网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
肿瘤标志物、血清炎症因子和协同共刺激分子B7-H6的表达在宫颈癌中的临床价值研究
作者:杨晓飞  于丽娜  刘京 
单位:石家庄市妇幼保健院 检验科, 河北 石家庄 050000
关键词:宫颈癌 肿瘤标志物 炎症因子 协同共刺激分子B7-H6 
分类号:R711
出版年·卷·期(页码):2021·49·第十一期(1267-1272)
摘要:

目的:探讨肿瘤标志物、血清炎症因子和协同共刺激分子B7-H6的表达在宫颈癌中的临床价值。方法:回顾性收集2019年6月至2020年9月于石家庄市妇幼保健院住院的宫颈病变患者80例,依据病理学检测结果分为宫颈癌组40例和宫颈慢性病变(宫颈良性组)40例;另选取40例同期体检正常人群作为对照组。比较3组肿瘤标志物[鳞状细胞癌抗原(SCCA)、癌胚抗原(CEA)、糖链抗原125(CA125)]水平,血清炎症因子[白介素-2(IL-2)、肿瘤坏死因子-α(TNF-α)、干扰素-γ(IFN-γ)]水平以及B7-H6表达。结果:与对照组比较,宫颈癌组与宫颈良性组SCCA、CEA、CA125、TNF-α、B7-H6表达水平均显著升高(P<0.05);且宫颈癌组SCCA、CEA、CA125、TNF-α、B7-H6表达水平显著高于宫颈良性组,差异有统计学意义(P<0.05)。与对照组比较,宫颈癌组和宫颈良性组IL-2、IFN-γ表达水平均显著降低;且宫颈癌组IL-2、IFN-γ表达水平显著低于宫颈良性组,差异均有统计学意义(P<0.05)。结论:肿瘤标志物(SCCA、CEA、CA125)、血清炎症因子(IL-2、IFN-γ、TNF-α)和协同共刺激分子B7-H6表达水平与宫颈癌的发展密切相关,可作为宫颈癌临床诊断的重要辅助指标。

Objective: To explore the clinical value of tumor markers, serum inflammatory factors and costimulatory molecule B7-H6 expression in cervical. Methods: A retrospective collection of 80 patients with cervical cancer lesions hospitalized in Shijiazhuang Maternity and Child Healthcare Hospital from June 2019 to September 2020. According to the pathologicalresults, they were divided into 40 cases of cervical cancer group and 40 cases of cervical benign group. Another 40 cases who were taking normal physical examination during the same period were selected as the control group. We compared the levels of tumor markers [squamous cell carcinoma antigen (SCCA), carcinoembryonic antigen (CEA), sugar chain antigen 125 (CA125)], serum inflammatory factor [interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ)] levels and the expression of costimulatory molecule B7-H6 among the three groups. Results: Compared with the control group, the expression levels of SCCA, CEA, CA125, TNF-α, B7-H6 in the cervical cancer group and the cervical benign group were significantly increased; and the levels of SCCA, CEA, CA125, TNF-α, B7-H6 in cervical cancer group were significantly higher than those of the cervical benign group; all the differences were statistically significant (P<0.05). Compared with the control group, the expression levels of IL-2 and IFN-γ in the cervical cancer group and the benign cervical group were significantly lower; and the expression levels of IL-2 and IFN-γ in the cervical cancer group were significantly lower than those in the benign cervical group; and all the differences were statistically significant (all P<0.05). Conclusion: The expression levels of tumor markers (SCCA, CEA, CA125), serum inflammatory factors (IL-2, IFN-γ, TNF-α) and costimulatory molecule B7-H6 are closely related to the development of cervical cancer and can be important auxiliary indexes for clinical diagnosis.

参考文献:

[1] BRAY F,FERLAY J,SOERJOMATARAM I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[2] 周晖,王东雁,罗铭,等.《FIGO 2018妇癌报告》—子宫颈癌指南解读[J].中国实用妇科与产科杂志,2019,35(1):95-103.
[3] 王宇,宋淑芳,刘凤.我国宫颈癌流行病学特征和发病高危因素的研究进展[J].中国妇幼保健,2019,34(5):1207-1209.
[4] 单玮,张涛,张铁军,等.我国女性人乳头瘤病毒(HPV)感染的流行病学现状[J].中华疾病控制杂志,2017,21(1):89-93.
[5] 夏昌发,乔友林,张勇,等.WHO全球消除宫颈癌战略及我国面临的挑战和应对策略[J].中华医学杂志,2020,100(44):3484-3488.
[6] PIMPLE S,MISHRA G,SHASTRI S.Global strategies for cervical cancer prevention[J].Curr Opin Obstet Gynecol,2016,28(1):4-10.
[7] 田宜畅,张颐.宫颈癌的诊断与治疗进展[J].北京医学,2019,41(12):1098-1100,1103.
[8] 杨碧锋,周晓明.血清炎症因子、肿瘤标志物、血管内皮生长因子和基质金属蛋白酶-9表达在宫颈癌中的临床价值研究[J].中国妇幼保健,2019,34(1):70-72.
[9] GUTIERREZ-SILERIO G Y,FRANCO-TOPETE R A,HARAMATI J,et al.Positive staining of the immunoligand B7-H6 in abnormal/transformed keratinocytes consistently accompanies the progression of cervical cancer[J].BMC Immunol,2020,21(1):1-9.
[10] 周晖,白守民,林仲秋.《2018 NCCN宫颈癌临床实践指南(第一版)》解读[J].中国实用妇科与产科杂志,2017,33(12):1255-1261.
[11] PATEL S,CHIPLUNKAR S.Host immune responses to cervical cancer[J].Curr Opin Obstet Gynecol,2009,21(1):54-59.
[12] VITKAUSKAITE A,URBONIENE D,CELIESIUTE J,et al.Circulating inflammatory markers in cervical cancer patients and healthy controls[J].J Immunotoxicol,2020,17(1):105-109.
[13] PARADKAR P H,JOSHI J V,MERTIA P N,et al.Role of cytokines in genesis,progression and prognosis of cervical cancer[J].Asian Pac J Cancer Prev,2014,15(9):3851-3864.
[14] TODORIC J,ANTONUCCI L,KARIN M.Targeting inflammation in cancer prevention and therapy[J].Cancer Prev Res,2016,9(12):895-905.
[15] 谭超月,张庆庆,李元,等.宫颈病变患者血清和阴道灌洗液中IL-2、IL-4、IFN-γ的表达及相关性研究[J].实用妇产科杂志,2018,34(7):515-518.
[16] ARTURO V M,ADRIANA G H,CARMEN L M,et al.Pleiotropic effects of IL-2 on cancer:its role in cervical cancer[J].Mediators Inflamm,2016,2016:2849523.
[17] 闫锡钊.TNF-α和TNFR1在宫颈癌组织中的表达及临床意义[D].唐山:华北理工大学,2016.
[18] 王晓娟,散琴,王月明,等.CEA、CA125、SCC-Ag、CA199及CYFRA21-1等肿瘤标志物在宫颈癌中诊断的价值和意义[J].海南医学院学报,2017,23(18):2573-2576.
[19] KOTOWICZ B,FUKSIEWICZ M,JONSKA-GMYREK J,et al.The assessment of the prognostic value of tumor markers and cytokines as SCCAg,CYFRA 21.1,IL-6,VEGF and sTNF receptors in patients with squamous cell cervical cancer,particularly with early stage of the disease[J].Tumour Biol,2016,37(1):1271-1278.
[20] ZHAO W,YU H,HAN Z,et al.Clinical significance of joint detection of serum CEA,SCCA,and bFGF in the diagnosis of lung cancer[J].Int J Clin Exp Pathol,2015,8(8):9506-9511.
[21] 王慧鸽,程玲,赖娟,等.血清AFP、CEA、CA199和CA125联合检测在宫颈癌诊断中的价值[J].医学综述,2020,26(1):169-173.
[22] ZAMANI N,GILANI M M,ZAMANI F,et al.Utility of pelvic MRI and tumor markers HE4 and CA125 to predict depth of myometrial invasion and cervical involvement in endometrial cancer[J].J Family Reprod Health,2015,9(4):177-183.
[23] SUN X,ZHAO J,MA L,et al.B7-H6 as an efficient target for T cell-induced cytotoxicity in haematologic malignant cells[J].Invest New Drugs,2021,39(1):24-33.
[24] BANU N,RIERA-LEAL A,HARAMATI J,et al.B7-H6,an immunoligand for the natural killer cell activating receptor NKp30,reveals inhibitory effects on cell proliferation and migration,but not apoptosis,in cervical cancer derived-cell lines[J].BMC Cancer,2020,20(1):1083.
[25] GUTIERREZ-SILERIO G Y,FRANCO-TOPETE R A,HARAMATI J,et al.Positive staining of the immunoligand B7-H6 in abnormal/transformed keratinocytes consistently accompanies the progression of cervical cancer[J].BMC Immunol,2020,21(1):9.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 559762 位访问者


 ©《现代医学》编辑部
联系电话:025-83272481;83272479
电子邮件: xdyx@pub.seu.edu.cn

苏ICP备09058541